Recurrent Herpes Simplex Virus (HSV) Keratitis or Conjunctivitis
Ongoing valacyclovir therapy is indicated for long-term prophylaxis against recurrent HSV conjunctivitis and keratitis. 11
Primary Indication
The key eye condition requiring continued oral valacyclovir is recurrent HSV keratitis or conjunctivitis in patients with a documented history of multiple episodes. According to the 2024 Ophthalmology guidelines, lower doses of oral antivirals are specifically considered for long-term prophylaxis against recurrent HSV conjunctivitis and keratitis 11.
Dosing for Prophylaxis
For long-term suppressive therapy:
- Valacyclovir 500 mg once daily is the standard prophylactic dose 1
- This is distinct from acute treatment doses (500 mg two or three times daily) 1
The evidence supporting this comes from high-quality research showing that prolonged antiviral use protects against ocular herpetic disease recurrences (RR 0.56; 95% CI 0.45-0.70, NNT 6) 2. Importantly, valacyclovir 500 mg daily has been shown to be as effective as acyclovir 400 mg twice daily in reducing recurrence rates (23.1% in both groups over 12 months) 3.
Secondary Indication: Chronic Varicella Zoster Virus (VZV) Disease
Patients with chronic sequelae from herpes zoster ophthalmicus may require prolonged treatment and/or long-term prophylaxis 11. This includes:
- Patients with persistent or recalcitrant acute/subacute VZV disease
- Those with chronic complications (stromal keratitis, uveitis, secondary glaucoma)
- Immunocompromised patients who need more aggressive treatment 1
For chronic VZV disease, the dose is adjusted according to clinical response, with some patients requiring prolonged treatment beyond the standard 7-day acute course 11.
Evidence for VZV Prophylaxis
Recent high-quality evidence from the 2026 Zoster Eye Disease Study (ZEDS) post-hoc analysis suggests that 12 months of prophylactic valacyclovir 1000 mg daily decreases the probability of subsequent zoster-related keratitis and iritis, with protective effects most pronounced in the early treatment period (0-6 months: HR 0.71; 95% CI 0.49-1.01) 4. The study supports 1 year of prophylaxis for patients with documented active keratitis or iritis within 1 year of herpes zoster ophthalmicus 4.
Clinical Algorithm for Ongoing Valacyclovir
Start long-term prophylaxis when:
HSV keratitis/conjunctivitis: Patient has history of ≥2 episodes of ocular HSV disease
- Dose: Valacyclovir 500 mg once daily
- Duration: Typically 1 year, reassess based on recurrence pattern
Herpes zoster ophthalmicus with complications: Patient has documented stromal keratitis, endothelial keratitis, or iritis within past year
- Dose: Valacyclovir 1000 mg daily
- Duration: 12 months minimum 4
Chronic VZV sequelae: Persistent keratitis, uveitis, or other chronic complications
- Dose: Adjust according to clinical response
- Duration: Prolonged, potentially indefinite 1
Important Caveats
- Renal function monitoring is essential: Caution is required in patients with impaired renal clearance 11. Dose adjustment needed if eGFR <45 mL/min/1.73 m²
- Not for acute treatment alone: The question specifically asks about "ongoing" therapy, which refers to prophylaxis, not acute episode management
- Topical antivirals may still be needed: Oral antivirals alone may not adequately prevent progression of HSV blepharoconjunctivitis; addition of topical antiviral treatment has been effective 11
- Avoid topical corticosteroids in active HSV: These potentiate HSV epithelial infections 11
The evidence strongly supports that prolonged antiviral use protects from both ocular and non-ocular recurrences (RR 0.56 for both) and specifically reduces stromal keratitis recurrences (RR 0.55; 95% CI 0.35-0.85) with a favorable safety profile 2.